Skip to main content
SpringerLink
Log in

Effects of reserpine treatment on the dopamine receptor binding of [3H/11C]nemonapride in the mouse and rat brain

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

We investigated the effect of reserpine treatment on the striatal uptake of a radiolabeled dopamine D2-like receptor ligand nemonapride (NEM). In mice, the uptake of the [3H]NEM in the striatum, cortex and cerebellum was enhanced by the reserpine pretreatment. Neither the ratio of striatum to cerebellum nor that to cortex was affected by the reserpine pretreatment. In rats,ex vivo autoradiography showed no effect of the reserpine treatment on the striatal uptake of [11C]NEM or the striatum to cortex ratio. The results suggest that the receptor binding of NEM was not significantly influenced by reserpine-induced depletion of endogenous dopamine probably because of its high affinity for the receptors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wagner HN, Burns HD, Dannais RF, Wong DF, Langstrom B, Duelfer T, et al. Imaging dopamine receptors in the human brain by positron emission tomography.Science 221: 1264–1266, 1983.

    Article  PubMed  CAS  Google Scholar 

  2. Mazière M, Coenen HH, Halldin C, Någren K, Pike VW. PET radioligands for dopamine receptors and re-uptake sites: Chemistry and biochemistry.Nucl Med Biol 19: 497–512, 1992.

    Google Scholar 

  3. Sawle GV, Brooks DJ. Positron emission tomography studies of neurotransmitter systems.J Neurol 237: 451–456, 1990.

    Article  PubMed  CAS  Google Scholar 

  4. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of dopamine-D2 receptor binding in the living human brain by positron emission tomography.Science 231: 258–261, 1986.

    Article  PubMed  CAS  Google Scholar 

  5. Seeman P, Guan HC, Van Tol HHM. Dopamine D4 receptors elevated in schizophrenia.Nature 365: 441–445, 1993.

    Article  PubMed  CAS  Google Scholar 

  6. Seeman P, Guan HC, Niznik HB. Endogeneous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain.Synapse 3: 96–97, 1989.

    Article  PubMed  CAS  Google Scholar 

  7. Ross SB, Jackson DM. Kinetic properties of the accumulation of [3H]raclopride in the mouse brainin vivo.Naunyn-Schmiedeberg’s Arch Pharmacol 340: 6–12, 1989.

    CAS  Google Scholar 

  8. Young LT, Wong DF, Goldman S, Minkin E, Chen C, Matsumura K, et al. Effects of endogenous dopamine on kinetics of [3H]N-methylspiperone and [3H]raclopride binding in the rat brain.Synapse 9: 188–194, 1991.

    Article  PubMed  CAS  Google Scholar 

  9. Inoue O, Kobayashi K, Tsukada H, Itoh T, Längström B, Difference inin vivo receptor binding between [3H]N-methylspiperone and [3H]raclopride in reserpine-treated mouse brain.J Neural Transm 85: 1–10, 1991.

    Article  CAS  Google Scholar 

  10. Hall H, Halldin C, Sedvall G. Gpp(NH)p stimulates [3H]raclopride binding to homogenates from human putamen and accumbens.Neurosci Lett 136: 79–82, 1992.

    Article  PubMed  CAS  Google Scholar 

  11. Hume SP, Myers R, Bloomfield PM, Opacka-Juffry J, Cremer JE, Ahier G, et al. Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography.Synapse 12: 47–54, 1992.

    Article  PubMed  CAS  Google Scholar 

  12. Sugawara M, Ishiwata K, Ido T, Iwata R, Ujiie A, Hatano K, et al. Synthesis and biodistribution of N-[(2RS,3RS)-1-benzyl-2-methyl-3-pyrrolidinyl]-5-chloro-2-methoxy-4-[11C]methylaminobenzamide, [11C]YM-09151-2: A newin vivo ligand for dopamine D2 receptors.CYRIC Annual Reports, Tohoku University 1986: 164–170, 1986.

    Google Scholar 

  13. Hatano K, Ishiwata K, Kawashima K, Hatazawa J, Itoh M, Ido T. D2-dopamine receptor specific brain uptake of carbon-11-labeled YM-09151-2.J Nucl Med 30: 515–522, 1989.

    PubMed  CAS  Google Scholar 

  14. Hatazawa J, Hatano K, Ishiwata K, Itoh M, Ido T, Kawashima K, et al. Measurement of D2 dopamine receptor-specific carbon-1l-YM-01951-2 binding in the canine brain by PET: Importance of partial volume correction.J Nucl Med 32:713–718, 1991.

    PubMed  CAS  Google Scholar 

  15. Hatazawa J, Ido T, Watabe K, Itoh M, Iwata R, Ishiwata K, et al. Age dependency in central dopamine D2 receptor specific and non-specific binding of [C-11]YM-09151-2.J Nucl Med 33: 897, 1992.

    Google Scholar 

  16. Ishiwata K, Inami K, Sasaki T, Nozaki T, Senda M. Characterization of [3H]nemonapride binding to mouse brain dopamine D2 receptors assessedin vivo andex vivo for metabolic modeling in PET studies.J Neural Transm 97: 119–133, 1994.

    Article  CAS  Google Scholar 

  17. Itoh M, Yamaguchi S, Meguro K, Fujiwara T, Iwata R, Ido T, et al. Neuroreceptor PET; Assessment of dopamine neurotransmission in dementia.In Brain, heart and tumor imaging. Updated PET and MRI. Ochi H, et al. (ed.), Elsevier Science B.V., pp. 101–105, 1995.

  18. Van Tol HHM, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine.Nature 350: 610–614, 1991.

    Article  PubMed  Google Scholar 

  19. Seeman P, Van Tol HHM. Dopamine D4-like receptor elevation in schizophrenia: cloned D2 and D4 receptors cannot be discriminated by raclopride competition against [3H]nemonapride.J Neurochem 64: 1413–1415, 1995.

    Article  PubMed  CAS  Google Scholar 

  20. Terai M, Usuda S, Kuroiwa I, Noshiro O, Maeno H. Selective binding of YM-09151-2, a new potent neuroleptic, to D2-dopaminergic receptors.Jpn J Pharmacol 33: 749–755, 1983.

    Article  PubMed  CAS  Google Scholar 

  21. Terai M, Hidaka K, Nakamura Y. Comparison of [3H]YM-09151-2 with [3H]spiperone and [3H]raclopride for dopamine D-2 receptor binding to rat striatum.Eur J Pharmacol 173: 177–182, 1989.

    Article  PubMed  CAS  Google Scholar 

  22. Ishiwata K, Seki H, Ishii K, Ishii S, Nozaki T, Senda M. Synthesis andin vivo evaluation of [11C]semotiadil, a benzothiazine calcium antagonist.Appl Radiat Isot 45: 439–443, 1994.

    Article  PubMed  CAS  Google Scholar 

  23. Jarvie KR, Niznik HB, Seeman P. Dopamine D2 receptors in canine brain: ionic effect on [3H]neuroleptic binding.Eur J Pharmacol 144: 163–171, 1987.

    Article  PubMed  CAS  Google Scholar 

  24. Seeman P, Guan HC, Civelli O, Van Tol HHM, Sunahara RK, Niznik HB. The cloned dopamine D2 receptor reveals different densities for dopamine receptor antagonist ligands. Implications for human positron emission tomography.Eur J Pharmacol 227: 139–146, 1992.

    Article  PubMed  CAS  Google Scholar 

  25. Chivers JK, Gommeren W, Leysen JE, Jenner P, Marsden CD. Comparison of thein-vitro receptor selectivity of substituted benzamide drugs for brain neurotransmitter receptors.J Pharm Pharmacol 40: 415–421, 1988.

    PubMed  CAS  Google Scholar 

  26. Fujiwara Y, Tomita H, Hikiji M, Kashihara K, Otsuki S, Ohnuki T, et al. Characterization of a cloned rat serotonin 5-HT1A receptor expressed in the HeLa cell line.Life Sci 52: 949–958, 1993.

    Article  PubMed  CAS  Google Scholar 

  27. Seeman P, Guan HC, Van Tol HHM. Schizophrenia: elevation of dopamine D4-like sites, using [3H]nemonapride and [125I]epidepride.Eur J Pharmacol 286: R3-R5, 1995.

    Article  PubMed  CAS  Google Scholar 

  28. Murray AM, Hyde TM, Knabel MB, Herman MM, Bigelow LB, Carter JM, et al. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia.J Neurosci 15: 2186–2191, 1995.

    PubMed  CAS  Google Scholar 

  29. Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression.Brain Res 681: 109–116, 1995.

    Article  PubMed  CAS  Google Scholar 

  30. Reynolds GP, Mason SL. Absence of detectable striatal dopamine D4 receptors in drug-treated schizophrenia.Eur J Pharmacol 281: R5-R6, 1995.

    Article  PubMed  CAS  Google Scholar 

  31. Reynolds GP. Dopamine D4 receptors schizophrenia?J Neurochem 66: 881–882, 1996.

    PubMed  CAS  Google Scholar 

  32. Wong DF, Wagner HN Jr, Tune LE, Dannals RF, Pearlson GD, Links JM, et al. Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics.Science 234: 1558–1563, 1986.

    Article  PubMed  CAS  Google Scholar 

  33. Farde L, Wiesel FA, Stone-Elander S, Halldin C, Nordström AL, Hall H, et al. D2 dopamine receptors in neurolepticnaive schizophrenic patients.Arch Gen Psychiatry 47: 213–219, 1990.

    PubMed  CAS  Google Scholar 

  34. Nordström AL, Farde L, Eriksson L, Halldin C. No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]NMSP.Psychiatry Res 61: 67–83, 1995.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Positron Medical Center, Tokyo Metropolitan Institute of Gerontology, 1-1 Nakacho, Itabashi, 173, Tokyo, Japan

    Kiichi Ishiwata, Kaori Onoguchi, Hinako Toyama, Junko Noguchi & Michio Senda

Authors
  1. Kiichi Ishiwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kaori Onoguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hinako Toyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Junko Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michio Senda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kiichi Ishiwata.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ishiwata, K., Onoguchi, K., Toyama, H. et al. Effects of reserpine treatment on the dopamine receptor binding of [3H/11C]nemonapride in the mouse and rat brain. Ann Nucl Med 11, 21–26 (1997). https://doi.org/10.1007/BF03164753

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03164753

Key words

Search

Navigation